By Billy Candra 
This significant finding, emerging from pioneering research conducted by scientists at St. Jude Children’s Research Hospital, marks a critical advancement in understanding the long-term health challenges faced by a growing population of childhood cancer survivors. The study, published today in The Lancet Oncology, provides an unprecedented quantification of the varied contributions of pediatric treatment exposures and genetic predisposition to the risk of developing a second primary cancer – a leading cause of mortality for these long-term survivors. By dissecting the relative impact of these factors at a population level, the research offers invaluable insights that are poised to reshape clinical approaches to survivor care and surveillance.
Deciphering the Multifaceted Risk of Secondary Cancers
The landscape of childhood cancer treatment has undergone a remarkable transformation over the past several decades, leading to dramatically improved survival rates. What was once a near-certain death sentence for many forms of pediatric cancer has evolved into a scenario where over 80% of children diagnosed with cancer now survive into adulthood. This triumph of modern medicine, however, has brought into sharper focus a new set of challenges: the late effects of cancer treatment, with secondary cancers being among the most devastating. These subsequent malignancies are not recurrences of the original cancer but entirely new cancers arising years or even decades after initial treatment.
Previous investigations have explored how specific treatment modalities, genetic predispositions, and lifestyle choices individually correlate with an elevated risk of secondary cancers. However, the true innovation of the St. Jude study lies in its ability to quantify the proportionate contribution of each factor to this risk within a large, diverse population of survivors. This distinction is crucial for developing targeted prevention and early detection strategies.
Dr. Yadav Sapkota, a corresponding author from the St. Jude Department of Epidemiology and Cancer Control, articulated the core finding: "We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition. We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level." This attribution moves the field beyond mere association to a more precise understanding of causality and impact.
Leveraging Unparalleled Cohort Data: St. Jude LIFE and CCSS
The robustness of these findings is underpinned by the study’s reliance on data from two of the world’s most extensive and meticulously curated childhood cancer survivor studies: the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS). Both housed at St. Jude Children’s Research Hospital, these cohorts collectively represent an unparalleled resource for understanding the long-term health trajectories of childhood cancer survivors.
The St. Jude LIFE study, initiated in 2007, prospectively evaluates survivors treated at St. Jude, providing comprehensive data on their health outcomes, treatment exposures, and genetic profiles. The CCSS, established in 1994, is an epidemiologic study of more than 35,000 five-year survivors of childhood cancer diagnosed between 1970 and 1999 at 26 institutions across North America, offering a broad historical perspective. Together, these cohorts comprise over 10,000 survivors with detailed genetic sequencing, treatment histories, and long-term follow-up on health outcomes, including the incidence of secondary cancers.
Dr. Greg Armstrong, MD, MSCE, chair of the St. Jude Department of Epidemiology and Cancer Control and a co-author, emphasized the unique nature of this data: "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing." This extensive dataset, encompassing detailed treatment exposures, genetic information, lifestyle factors, and comprehensive records of secondary cancer diagnoses, allowed researchers to perform an unprecedented evaluation of these contributing elements.
Radiation’s Enduring Legacy: A Major Contributor
Among the factors analyzed, radiation exposure emerged as the most significant contributor to secondary cancer risk, accounting for approximately 40% or more of the overall risk. This finding, while not entirely new in its observation of radiation’s adverse effects, provides a crucial quantification that reinforces existing medical consensus and ongoing efforts to minimize its use.
Historically, radiation therapy was a cornerstone of treatment for many pediatric cancers, highly effective in eradicating primary tumors. However, early understanding of its long-term sequelae was limited. Over time, as survival rates improved and survivors lived longer, the association between radiation exposure and subsequent malignancies – including sarcomas, breast cancer, and thyroid cancer – became increasingly clear. This growing awareness has already spurred significant shifts in modern oncology, with clinicians actively seeking to reduce radiation doses, employ more targeted delivery methods, or eliminate radiation altogether in favor of alternative therapies where possible. The St. Jude study provides further empirical support for these evolving treatment paradigms, underscoring the necessity of continued vigilance in optimizing treatment protocols to balance immediate efficacy with long-term safety.
The Surprising Weight of Genetics: Beyond Chemotherapy
While the impact of radiation was stark, the study unveiled more nuanced and, in some cases, counter-intuitive relationships concerning chemotherapy and genetic predisposition. Chemotherapy, another vital component of childhood cancer treatment, contributed between 8% and 35% of subsequent cancer risk, depending on the specific cancer type. The late effects of various chemotherapeutic agents, such as anthracyclines, alkylating agents, and topoisomerase inhibitors, have been well-documented, including risks for cardiac toxicity, infertility, and secondary leukemias and solid tumors.
However, the revelation regarding genetic predisposition proved particularly striking. The researchers meticulously investigated hundreds of common genetic variants previously linked to cancer development in the general population, aggregated into what is known as a polygenic risk score (PRS). They also considered some rare genetic variants. This polygenic risk score approach revealed that genetic factors contributed significantly, ranging from 5% to 37% of the risk, depending on the specific secondary cancer type.
This finding challenges "conventional wisdom in the field," as Dr. Sapkota noted, stating, "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers." This insight suggests that while chemotherapy’s immediate and acute side effects are often pronounced, the underlying genetic susceptibility of an individual plays a profound and previously underappreciated role in their long-term risk for secondary malignancies.
Dr. Yutaka Yasui, PhD, also from the St. Jude Department of Epidemiology and Cancer Control and a co-author, commented on the utility of PRS: "Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population. Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures." This suggests that while PRS may not be universally applicable for broad population screening, their predictive power dramatically increases when contextualized within the unique environment of childhood cancer survivors and their specific treatment histories.
Lifestyle Factors: A Long-Term Perspective
In contrast to the significant contributions of treatment and genetics, lifestyle factors such as diet and exercise appeared to play a comparatively smaller role in the immediate risk of secondary cancers in this study, accounting for only 1% to 6% of the risk. This observation, however, comes with an important caveat. The survivor cohort in this study was primarily comprised of individuals in their 20s and 30s. At this relatively young age, the cumulative impact of lifestyle choices on cancer development may not yet be fully apparent. Many chronic diseases, including certain cancers, often manifest after decades of exposure to specific lifestyle risk factors.
Dr. Sapkota acknowledged this nuance: "We know healthy lifestyle choices are important for survivors. In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac wellbeing, so it is still important for clinicians to encourage — and patients to seek — a healthy lifestyle." This emphasizes that while lifestyle’s direct contribution to secondary cancer risk at younger ages might be modest, its broader importance for overall long-term health and the prevention of other treatment-related complications remains undeniable.
Transforming Clinical Care and Surveillance Strategies
The implications of this research for the clinical management of childhood cancer survivors are profound and far-reaching. Historically, surveillance protocols for secondary cancers have heavily emphasized treatment exposures, particularly radiation history. While this remains critical, the St. Jude study advocates for a more holistic, personalized approach that integrates genetic information.
"Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk," Dr. Sapkota explained. "Our study suggests that we need to better account for genetic predisposition in this population." For survivors identified with a strong genetic predisposition, more aggressive and frequent cancer screenings could be warranted. This proactive approach aims to detect secondary cancers at their earliest, most treatable stages, significantly improving prognoses.
Patient advocacy groups and organizations dedicated to long-term survivor care are likely to embrace these findings as a powerful tool for empowering survivors. Armed with knowledge about their unique combination of treatment-related, genetic, and lifestyle risk factors, survivors can engage more effectively with their healthcare providers, advocating for tailored screening schedules and personalized preventive measures. This shift from a generalized surveillance model to a precision medicine approach holds the potential to dramatically improve long-term health outcomes for this vulnerable population.
The Road Ahead: Prevention, Detection, and Extended Lives
The ultimate goal of this research is to extend and enrich the lives of childhood cancer survivors. Secondary cancers, as Dr. Sapkota reiterated, "remain the leading cause of mortality for childhood cancer survivors." By quantifying the contributions of treatment, genetics, and lifestyle, the scientific community now possesses a clearer roadmap for focusing efforts.
This includes:
- Refining Treatment Protocols: Continuing the trend of minimizing radiation and optimizing chemotherapy regimens based on individual risk profiles.
- Advanced Risk Stratification: Developing sophisticated models that integrate genetic data with treatment histories to identify high-risk individuals who would benefit most from intensive surveillance.
- Personalized Screening: Implementing tailored screening protocols, potentially including more frequent imaging, biopsies, or blood tests, based on an individual’s specific genetic and treatment-related risk factors for particular secondary cancers.
- Targeted Prevention Strategies: Investigating preventive interventions for high-risk groups, potentially including chemoprevention or lifestyle interventions specifically designed to mitigate genetically influenced risks.
- Enhanced Patient Education: Providing survivors and their families with clear, actionable information about their individualized risk profiles, empowering them to make informed health decisions and partner with their care teams.
The findings from St. Jude Children’s Research Hospital represent a pivotal moment in the ongoing quest to improve the health and longevity of childhood cancer survivors. This study not only deepens our understanding of the complex interplay between genetic susceptibility and treatment effects but also provides a tangible framework for translating this knowledge into more effective, personalized clinical care. As medicine continues to advance, the insights gleaned from these comprehensive cohort studies will undoubtedly pave the way for a future where the triumph of surviving childhood cancer is consistently followed by a lifetime of good health.
Authors and Funding
The study’s first author is Achal Neupane, of St. Jude. The study’s other authors are Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison and Yutaka Yasui; St. Jude; Qi Liu; University of Alberta; Cindy Im, Lucie Turcotte and Joseph Neglia; University of Minnesota; Monica Gramatges, Baylor College of Medicine; Rebecca Howell, University of Texas MD Anderson Cancer Center and Smita Bhatia; University of Alabama at Birmingham.
The study was supported by grants from the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547 and CA21765) and ALSAC, the fundraising and awareness organization of St. Jude.
